OTLK

Outlook Therapeutics Inc

0.4681

Oct 30 • 3:59 PM ET -0.0254 (-5.15%)

0.4740

Aftermarket • 7:59 PM ET +0.0059 (1.26%)

Healthcare Biotechnology USA Micro NASD

Peers: EYPT OCUL KLRS KOD OCS LENZ ANNX IRD ALDX AURA

| Held by: VTI VXF

Scroll to Statements

Index	-
Market Cap	113.96M
Enterprise Value	121.15M
Income	-
Sales	-
Book/sh	-0.06
Cash/sh	0.05
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	17
IPO	Jun 14, 2016

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	10.14
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.63
Current Ratio	0.81
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-
EPS next Y	-0.18
EPS next Q	-0.07
EPS this Y	73.18%
EPS next Y	63.02%
EPS next 5Y	-
EPS past 3/5Y	33.96% 33.18%
Sales past 3/5Y	- -
EPS Y/Y TTM	86.28%
Sales Y/Y TTM	-
EPS Q/Q	90.10%
Sales Q/Q	-
Earnings	Aug 14 BMO
EPS/Sales Surpr.	-12.50% -99.07%

Insider Own	12.64%
Insider Trans	61.78%
Inst Own	27.22%
Inst Trans	20.42%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-12.79%
SMA50	-21.97%
SMA200	-29.37%
Trades

Shs Outstand	243.45M
Shs Float	212.68M
Short Float	15.32%
Short Ratio	3.18
Short Interest	32.59M
52W High	2.54 -81.55%
52W Low	0.16 190.56%
Volatility	8.51% 9.35%
ATR (14)	0.05
RSI (14)	36.01
Beta	0.73
Rel Volume	0.47
Avg Volume	10.24M
Volume	4,794,550

Perf Week	-9.86%
Perf Month	-18.59%
Perf Quarter	-48.73%
Perf Half Y	78.53%
Perf YTD	-70.37%
Perf Year	-62.25%
Perf 3Y	-95.69%
Perf 5Y	-98.87%
Perf 10Y	-99.93%
Recom	1.50
Target Price	5.03
Prev Close	0.49
Price	0.47
Change %	-5.15%

Consensus

Buy

Avg. Price Target

$5.03

Implied Upside

+974.6%

Analysts6incl. previous ratings

Rating Distribution2 Buy · 4 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jul 27, 2026	Upgrade	BBTIG Research	Neutral → Buy	$4	+754.5%
May 18, 2026	Downgrade	BBTIG Research	Buy → Neutral
Aug 29, 2025	Downgrade	HH.C. Wainwright	Buy → Neutral
Aug 28, 2025	Downgrade	GGuggenheim	Buy → Neutral
Dec 02, 2024	Downgrade	CChardan Capital Markets	Buy → Neutral
Mar 27, 2024	Upgrade	BBTIG Research	Neutral → Buy	$50	+10,581.5%
Feb 15, 2024	Upgrade	CChardan Capital Markets	Neutral → Buy	$3	+540.9%
Jan 25, 2024	Upgrade	GGuggenheim	Neutral → Buy
Dec 27, 2023	Upgrade	CCapitalOne	Equal Weight → Overweight	$5	+968.1%
Aug 31, 2023	Downgrade	HH.C. Wainwright	Buy → Neutral	$5 → $1	+113.6%
Aug 31, 2023	Downgrade	CChardan Capital Markets	Buy → Neutral
Aug 30, 2023	Downgrade	GGuggenheim	Buy → Neutral
Aug 30, 2023	Downgrade	CCapitalOne	Overweight → Equal Weight
Aug 30, 2023	Downgrade	CCantor Fitzgerald	Overweight → Neutral	$4.50 → $1	+113.6%
Aug 30, 2023	Downgrade	BBTIG Research	Buy → Neutral
Jul 13, 2023	Initiated	CCapitalOne	Overweight	$5	+968.1%
Apr 03, 2023	Initiated	GGuggenheim	Buy	$5	+968.1%
Feb 06, 2023	Initiated	CCantor Fitzgerald	Overweight	$4	+754.5%
Oct 31, 2022	Initiated	BBTIG Research	Buy	$7	+1,395.4%
Sep 13, 2022	Initiated	CChardan Capital Markets	Buy	$10	+2,036.3%

Oct-09-26 08:30AM	Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer (GlobeNewswire) +6.19%
Oct-06-26 09:20AM	Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company's Next Chapter in Virtual Investor Discussion (GlobeNewswire)
Oct-01-26 09:01AM	Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA (bevacizumab-vikg) (GlobeNewswire)
Sep-28-26 07:31AM	Kodiak Sciences Stock Pops 64% After Eye-Disease Drugs Pass Key Trial (Barrons.com)
Sep-11-26 07:00AM	Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand (GlobeNewswire)
09:10AM	Loading…
Sep-10-26 09:10AM	Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA in Virtual Investor CEO Connect Segment (GlobeNewswire)
Aug-27-26 04:05PM	Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA (GlobeNewswire)
09:01AM	Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor "Why Now" On-Demand Conference (GlobeNewswire)
Aug-14-26 07:15AM	Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA (GlobeNewswire) -14.90%
Aug-13-26 06:31AM	Why Did OTLK Stock Crash In Pre-Market Today? (Stocktwits) -19.20%
Aug-12-26 09:45PM	Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants (GlobeNewswire)
04:01PM	Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants (GlobeNewswire)
Aug-06-26 08:45AM	Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026 (GlobeNewswire) -5.58%
Jul-27-26 01:45PM	Outlook Therapeutics Recently Approved Therapy Could Become Preferred Anti-VEGF Treatment Option In $8.5B US Retina Market, Says BTIG (Stocktwits) -24.20%
07:13AM	Outlook Therapeutics wins FDA approval for Lytenava in wet AMD (Pharmaceutical Technology)
07:12AM	Loading…
07:12AM	Outlook Therapeutics shares climb after FDA clears LYTENAVA for wet AMD (InvestorsHub)
07:00AM	FDA scientists question Capricor data; Legend CEO steps down (BioPharma Dive)
02:47AM	OTLK Stock Jumps Overnight After FDA Approval Of Wet AMD Drug Analysts See Nearly 300% Upside (Stocktwits)
Jul-24-26 08:30PM	FDA Showdown Week: CAPR, NRXP, REPL And MRNA Face Make-Or-Break Regulatory Decisions (Stocktwits) +6.44%
07:47PM	OTLK Stock Surges After FDA Ends Decade-Long Wait For Ophthalmic Bevacizumab (Stocktwits)
02:40PM	Outlook Therapeutics Announces LYTENAVA FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD (GlobeNewswire)
Jul-23-26 01:00PM	OTLK Stock Generates Buzz Ahead Of FDA Decision On Wet AMD Therapy Retail Says Favorable Verdict Could Cause A Big Boom (Stocktwits)
Jun-16-26 01:47PM	OTLK Stock Soars 28% After FDA Sets July Date For Lytenava Decision (Stocktwits) +35.34%
08:02AM	Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA (bevacizumab-vikg) as a Treatment for Wet AMD (GlobeNewswire)
Jun-01-26 01:05PM	OTLK Stock Surges On FDA Lytenava Application Resubmission After Successful Appeal (Stocktwits) +15.48%
08:46AM	Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA (bevacizumab-vikg) (GlobeNewswire)
May-28-26 04:00PM	Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) +26.39%
01:38PM	OTLK Stock Rocket Nearly 140%: Lytenava Dispute Resolution With FDA Pushes Stock On Track For Best Week On Record (Stocktwits)
May-27-26 01:10AM	Why RDW, TE, OTLK Stocks Posted Double-Digit Gains On Tuesday (Stocktwits) +46.30%
May-26-26 09:08AM	OTLK Stock Surges Over 50% Pre-Market, Breaches Key Technical Milestone Whats Behind This Massive Rally? (Stocktwits) +29.14%
07:00AM	Loading…
07:00AM	Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA (bevacizumab-vikg) (GlobeNewswire)
May-15-26 04:05PM	Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-23-26 04:05PM	Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering (GlobeNewswire) +9.83%
Apr-22-26 08:30AM	Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -9.14%
Apr-21-26 09:05AM	Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA (bevacizumab-vikg) (GlobeNewswire) -13.68%
Apr-07-26 08:50AM	Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA (bevacizumab-vikg) Accepted by FDA (GlobeNewswire) +6.18%
Mar-25-26 04:05PM	Outlook Therapeutics Announces Closing of $5.0 Million Public Offering (GlobeNewswire)
Mar-24-26 07:00AM	Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering (GlobeNewswire) -38.06%
Mar-23-26 05:30PM	Outlook Therapeutics Announces Proposed Public Offering (GlobeNewswire) -8.91%
Mar-16-26 08:05AM	Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note (GlobeNewswire) -10.69%
Mar-05-26 04:15PM	Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA (bevacizumab-vikg) (GlobeNewswire)
Feb-19-26 09:00AM	Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA (bevacizumab gamma) in Switzerland (GlobeNewswire) +6.10%
Feb-17-26 09:15AM	Oncobiologics, Inc. (OTLK) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -13.82%
08:05AM	Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-11-26 08:45AM	Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter (GlobeNewswire) +11.52%
Jan-07-26 09:53AM	OTLK Stock Crashes 67% in a Week: Here's What You Need to Know (Zacks) +11.43%
Jan-06-26 08:35AM	Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development (GlobeNewswire)
Jan-02-26 07:29AM	Baidu, ASML, furniture stocks rise; Outlook Therapeutics sinks (Investing.com) -58.23%
Jan-01-26 04:35PM	FDA says cannot approve Outlook Therapeutics ONS-5010 BLA in present form (TipRanks)
Dec-31-25 04:15PM	Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD (GlobeNewswire) -15.28% -58.23%
Dec-26-25 05:00PM	Outlook Therapeutics Announces New Employment Inducement Grants (GlobeNewswire) +8.79%
Dec-19-25 09:30AM	Oncobiologics, Inc. (OTLK) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
08:05AM	Outlook Therapeutics Reports Financial Results for Fiscal Year 2025 (GlobeNewswire)
Dec-16-25 11:39AM	Micron Dominates Barchart's Top 100 with Killer VolumeYour Buy Signal? (Barchart) +13.82%
Nov-24-25 09:05AM	Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-13-25 08:30AM	Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD (GlobeNewswire) +14.84%
Nov-03-25 08:35AM	Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010 (GlobeNewswire)
Sep-29-25 08:45AM	Outlook Therapeutics Provides Update on Type A Meeting with FDA (GlobeNewswire) +9.27%
Sep-03-25 08:35AM	Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS) (GlobeNewswire)
Sep-02-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
08:35AM	Outlook Therapeutics Requests Type A Meeting with FDA (GlobeNewswire)
Aug-29-25 10:38AM	OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug (Zacks) -21.91%
09:38AM	Marvell downgraded, Dollar Tree upgraded: Wall Street's top analyst calls (The Fly)
Aug-28-25 11:15AM	FDA Rejects Outlook Therapeutics Eye Drug For Second Time (Benzinga) -54.11%
10:30AM	BC-Most Active Stocks (Associated Press Finance)
06:30AM	Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD (GlobeNewswire)
Aug-18-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +18.38%
Aug-14-25 09:15AM	Oncobiologics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +14.08%
08:05AM	Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update (GlobeNewswire)
Jul-30-25 05:50AM	New Strong Buy Stocks for July 30th (Zacks)
Jul-24-25 09:00AM	Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase (GlobeNewswire)
Jul-22-25 08:45AM	Outlook Therapeutics Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference (GlobeNewswire)
08:40AM	JTC Team Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference Now Live (ACCESSWIRE)
Jul-01-25 08:05AM	Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer (GlobeNewswire)
Jun-18-25 09:05AM	Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event (GlobeNewswire)
Jun-11-25 05:06AM	Outlooks wet AMD treatment accepted by SMC for NHS Scotland (Pharmaceutical Technology)
Jun-10-25 08:05AM	Outlook Therapeutics Announces SMC Recommendation of LYTENAVA (bevacizumab gamma) for the Treatment of Wet AMD (GlobeNewswire)
Jun-02-25 07:00AM	Outlook Therapeutics Announces Commercial Launch of LYTENAVA (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD (GlobeNewswire)
May-23-25 06:30AM	Outlook Therapeutics Announces Pricing of $13.0 Million Public Offering (GlobeNewswire)
May-22-25 04:01PM	Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants (GlobeNewswire)
May-15-25 04:01PM	Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update (GlobeNewswire)
Apr-08-25 08:45AM	Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD (GlobeNewswire)
Mar-20-25 05:24PM	Outlook Therapeutics files to sell 21.72M shares of common stock for holders (SeekingAlpha)
Feb-28-25 08:05AM	Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration (GlobeNewswire) +8.70%
Feb-19-25 09:00AM	Outlook Therapeutics Participates in the Virtual Investor Top 5 for '25 On-Demand Conference (GlobeNewswire)
Feb-14-25 08:05AM	Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update (GlobeNewswire)
Feb-04-25 09:05AM	Outlook Therapeutics Participates in Virtual Investor What This Means Segment (GlobeNewswire)
Jan-31-25 08:05AM	Outlook Therapeutics Appoints Faisal G. Sukhtian as Chairman of the Board of Directors (GlobeNewswire)
Jan-23-25 09:05AM	Outlook Therapeutics Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD (GlobeNewswire)
Jan-22-25 09:05AM	Outlook Therapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar (GlobeNewswire) -8.93%
Jan-16-25 12:09PM	Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug (Benzinga)
06:00AM	Outlook Therapeutics Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial (GlobeNewswire)
Jan-08-25 09:15AM	Outlook Therapeutics Participates in Virtual Investor What This Means Segment (GlobeNewswire) -5.22%
Dec-30-24 07:45AM	Outlook Therapeutics Stock Surges on Positive Outlook Despite Loss (GuruFocus.com) -7.46%
Dec-28-24 10:50PM	Outlook Therapeutics Reports 2024 Financial Results (TipRanks)
08:10AM	Outlook Therapeutics provides ONS-5010/LYTENAVA update (TipRanks)
Dec-27-24 08:05AM	Outlook Therapeutics Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update (GlobeNewswire) +18.24%
Dec-13-24 04:30PM	Outlook Therapeutics Streamlines Operations (GlobeNewswire)
Dec-04-24 08:05AM	Outlook Therapeutics Announces NICE Recommendation of LYTENAVA (bevacizumab gamma) for the Treatment of Wet AMD (GlobeNewswire) -8.03%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sukhtian Ghiath M.	Director	Aug 12 '26	Buy	0.99	2,525,252	2,499,999	24,617,320	Aug 14 07:52 PM
Sukhtian Faisal Ghiath	Director	Jul 29 '26	Buy	1.05	95,398	99,996	220,972	Jul 29 03:19 PM
Haddadin Yezan Munther	Director	Jun 02 '26	Buy	0.83	29,000	24,145	66,167	Jun 03 06:03 PM
Sukhtian Ghiath M.	Director	May 28 '26	Buy	0.59	8,539,709	5,000,000	22,092,068	Jun 01 09:30 PM
Sukhtian Faisal Ghiath	Director	May 27 '26	Buy	0.41	122,174	50,006	125,574	May 27 03:29 PM
Haddadin Yezan Munther	Director	May 26 '26	Buy	0.44	34,000	14,960	37,167	May 27 03:24 PM
THURMAN RANDY H	Director	May 26 '26	Buy	0.43	5,000	2,145	5,593	May 27 03:20 PM
HILZINGER KURT J	Director	May 26 '26	Buy	0.44	400,000	176,520	423,655	May 27 03:15 PM

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

PresidentMr. Robert Charles Jahr

CFOMr. Kevin Lundquist

Senior Vice President of Licensing and M&AMr. Joel Prieve

Senior Vice President of Medical AffairsDr. Surendra Sharma M.D.

Senior Vice President of Clinical Development & Regulatory AffairsDr. Jennifer M. Kissner Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OTLK

Outlook Therapeutics Inc

Upgrade your Finviz experience